WO2011156777A1 - Utilisation du mir-210 sanguin pour le pronostic du cancer - Google Patents

Utilisation du mir-210 sanguin pour le pronostic du cancer Download PDF

Info

Publication number
WO2011156777A1
WO2011156777A1 PCT/US2011/040078 US2011040078W WO2011156777A1 WO 2011156777 A1 WO2011156777 A1 WO 2011156777A1 US 2011040078 W US2011040078 W US 2011040078W WO 2011156777 A1 WO2011156777 A1 WO 2011156777A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
rna
prognosis
samples
cancer
Prior art date
Application number
PCT/US2011/040078
Other languages
English (en)
Inventor
Muneesh Tewari
Patrick S. Mitchell
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Publication of WO2011156777A1 publication Critical patent/WO2011156777A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • MicroRNAs are small RNAs, typically 22 nucleotides in length that influence gene expression networks by repressing target messenger RNAs via specific base-pairing interactions. Over-expression and silencing of specific miRNA have been described in a number of diseases, including cancer. The continuing discovery of
  • microRNA dysregulation contributes to cancer diagnosis and therapy and the identification of specific diagnostic biomarkers and therapeutic targets is needed to provide new and useful tools for improved management of disease.
  • hsa-miR-210 was significantly correlated with other markers of hypoxia, and high levels of hsa-miR-210 were associated with locoregional disease recurrence. Further, cellular levels of miR-210 were suggested to be useful in diagnosing cancer (Croce et al., U.S. Patent No. 7,670,840; Croce et al., US2008/0306006, and Croce et al. US2008/0306017).
  • One embodiment of the invention is a method of prognosing cancer comprising the steps of collecting at least one first blood sample from a subject with cancer; administering to the subject an anti-angiogenic treatment; collecting at least one second blood sample following said treatment; measuring levels of miR-210 in the samples; comparing levels of miR-210 before and after treatment; and providing a prognosis, wherein the prognosis is based on the difference in the levels of miR-210 between the samples.
  • One aspect of the method, where the levels of miR-210 change following the treatment, is to provide a favorable or unfavorable prognosis, depending on the direction of the change.
  • Another aspect of the invention, where the levels of miR-210 do not increase following the treatment, is to provide no change in the prognosis of the subject.
  • measuring levels of miR-210 comprises the steps of extracting RNA from the first and second samples; and contacting said RNA with at least one nucleic acid probe to measure blood levels of miR-210.
  • the RNA is preferably extracted from serum or plasma obtained from each sample, most preferably from serum.
  • the levels of miR-210 may be measured by quantitative PCR.
  • the RNA may contacted with a microarray comprising a multiplicity of single stranded oligonucleotides to measure blood levels of miR-210.
  • a control RNA can be included in the measurement, either added to the samples prior to measurements, or chosen from among RNA known to be present in the samples.
  • the multiplicity of blood samples may be obtained from a multiplicity of subjects.
  • the subjects can be ones having the same type of cancer, or may be healthy normal subjects.
  • the method may preferably include calculating an average level of miR-210 in the multiplicity of samples.
  • the method further comprises a step of comparing the level of miR-210 in the first blood sample of the subject with cancer to the average level of miR-210 in a normal subject, and a further step of providing a prognosis.
  • the method provides a favorable prognosis for the subject when undergoing an anti-angiogenic treatment.
  • the method provides an unfavorable prognosis for an anti-angiogenic treatment.
  • the method provides a favorable prognosis for response to an anti-angiogenic treatment.
  • Another aspect of the method involves collection of a multiplicity of samples that are collected from the subject with cancer at various times following anti- angiogenic treatment.
  • the method further comprises comparing the level of miR-210 in the first sample with the level of miR-210 in each of the multiplicity of second samples. Where the levels of miR-210 increase over time following anti-angiogenic treatment, the method provides a favorable prognosis. Where levels do not increase, the method provides an alternate treatment modality, preferably comprising administering a pro-angiogenic treatment and/or vascular-stabilizing agent, followed by administering a cytotoxic drug.
  • Another aspect of the method is where a blood sample is taken from the subject before treatment, and the level of miR-210 in the pre-treatment sample is used to determine a prognosis for response to anti-angiogenic therapy.
  • the level of miR-210 in the pre-treatment sample is elevated, the elevated level denotes that the tumor has already adapted to hypoxia, and will be less sensitive to anti-angiogenic therapy.
  • Such an indication of reduced sensitivity to anti-angiogenic therapy indicates a different initial therapeutic approach, for example, treatment with an agent that will render the cancer more sensitive to subsequent therapy with an anti-angiogenic agent, or with agents that increase tumor perfusion.
  • a decrease in miR-210 levels following such sensitizing treatment may be used to indicate that the subject is ready to receive anti- angiogenic therapy.
  • a high level of miR-210 in the pre- treatment sample indicates that the tumor has already maximally adapted to hypoxia and has reached a tipping point, and that anti-angiogenic therapy will lead to a favorable response.
  • nucleic acid probe that is one or more single stranded nucleic acid molecules, preferably one or more nucleic acids that hybridize with the nucleic acid having the sequence of SEQ ID NO: 1 or SEQ ID NO:2.
  • the prognosis is in the form of a report, preferably a result of a computer calculation, most preferably, a computer that causes the report to be produced in a tangible medium.
  • a computing device may be used as to store data to be configured into a prognosis in the form of a report.
  • the report may be generated as the result of data indicative of, among other things miR-210 levels in various samples, the data having been subject to a method of prognosing by the computing device, the result being displayed on a display.
  • Another aspect of the method is where, instead of blood, another bodily fluid is used, which fluid may be selected from the group consisting of urine, semen, seminal fluid, seminal plasma, prostatic fluid, pre-ejaculatory fluid (Cowper's fluid), pleural effusion, tears, saliva, sputum, sweat, biopsy, ascites, cerebrospinal fluid, amniotic fluid, lymph, marrow, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions, breast secretions, ovarian cyst secretions, or fluid extracted from a tissue sample.
  • fluid may be selected from the group consisting of urine, semen, seminal fluid, seminal plasma, prostatic fluid, pre-ejaculatory fluid (Cowper's fluid), pleural effusion, tears, saliva, sputum, sweat, biopsy, ascites, cerebrospinal fluid, amniotic fluid, lymph, marrow, cervical secretions, vaginal secretions, end
  • Figures 1A-F shows levels of miRNA in blood from patients with prostate cancer.
  • Fig. 1 A is a graph showing circulating miRNAs in sera pooled from patients with advanced prostate cancer or healthy donors by TLDA profiling.
  • mir-100, miR- 141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, and miR-425-5p met biomarker criterion of >5-fold change (unadjusted P ⁇ 0.05, student's t-test) in pooled sera from CaP patients relative to normal controls.
  • Figs. 1B-1F The graphs in the upper panels show miRNA levels by
  • TaqMan® miRNA qRT-PCR (P value assigned by Wilcoxon signed-rank test), miRNA copies/ ⁇ serum. Horizontal bars: mean value +/- SEM of miRNA copies/ ⁇ serum for each group.
  • the graphs in lower panels show receiver operating characteristic (ROC) curves. AUC, area under the curve; CaP, prostate cancer patient sera; FC, fold-change; N, normal sera (PSA neg /DRE ne g).
  • Figures 2A-E show miR-210 levels (copies per microliter serum) compared to miR-141, miR-200a, miR-200c, and miR-375 for prostate cancer responders to therapy (i.e., in a period of declining PSA) or not responding (i.e., in a period of not changing or increasing PSA).
  • microRNA or "miRNA” means a small, noncoding RNA sequence of 5 to 40 nucleotides in length that can be detected in a biological specimen.
  • Some microRNAs are derived from hairpin precursors processed, for example, by the enzyme DICER to a mature species, for example, about 18-28 nucleotides, preferably 21-23 nucleotides.
  • Biological fluid or "body fluid” can be used interchangeably and refer to a fluid isolated from a mammal.
  • Such fluids include, but are not limited to, blood fluid, a blood fluid fraction, serum, plasma, urine, saliva, lymph, tears, pleural effusion, mucus, ascitic fluid, respiratory secretions such as bronchial secretions, amniotic fluid, cerebrospinal fluid, breast secretions, ovarian cyst fluid, and fluid isolated from a tissue.
  • biological sample refers to all biological fluids and excretions isolated from any given subject.
  • samples include, but are not limited to, blood and fractions thereof, blood serum, blood plasma, urine, excreta, semen, seminal fluid, seminal plasma, prostatic fluid, pre-ejaculatory fluid (Cowper's fluid), pleural effusion, tears, saliva, sputum, sweat, biopsy, ascites, cerebrospinal fluid, amniotic fluid, lymph, marrow, cervical secretions, vaginal secretions, endometrial secretions,
  • gastrointestinal secretions bronchial secretions, breast secretions, ovarian cyst secretions, hair, and tissue fluid samples.
  • MicroRNA Variants are common, for example, among different animal species.
  • variation at the 5' and 3' ends of microRNAs are common, and can be the result of imprecise cleavage by enzymes such as DICER during maturation as well as non- templated addition following maturation.
  • DICER enzymes
  • These variants demonstrate a scope of acceptable variation in the sequence of the microRNAs that does not impair function or the ability to detect the microRNA(s).
  • Some simple 3' end modification may affect the ability to detect the miRNA by qRT-PCR directed against a canonical species, but not by microarray.
  • nucleic acid can be used interchangeably and refer to nucleotide sequences of any length, including DNA and RNA.
  • the nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a nucleotide sequence, for example by DNA or RNA polymerase, or by chemical reaction.
  • Nucleic acids may be single stranded or double stranded, or may contain portions of both double and single stranded sequence. A single strand can provide a probe that hybridizes to a target sequence.
  • a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the nucleotide sequence.
  • the sequence of nucleotides may be interrupted by non-nucleotide components.
  • a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
  • modifications include, for example, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl, phosphonates, phosphotriesters, phosphoamidates, cabamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, antibodies, signal peptides, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e,g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleot
  • any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports.
  • the 5' and 3' terminal OH can be phosphorylated or substituted with amines or organic capping groups moieties of from 1 to 20 carbon atoms.
  • Other hydroxyls may also be derivatized to standard protecting groups.
  • Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2'-0-methyl-, 2'-0-allyl, 2'-fluoro- or 2'- azido-ribose, carbocyclic sugar analogs, . alpha. -anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside.
  • One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(O)
  • each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C). optionally containing an ether (— O--) linkage, aryl, alkenyl, cycloalkyl,
  • an "anti-angiogenic” factor or an “angiogenic inhibitor” are compounds used to stop the growth of tumors and progression of cancers by limiting the pathologic formation of new blood vessels (angiogenesis). These compounds include bevacizumab, cetuximab, erlotinib, serofenib, sunitinib, temsirolimus, everolimus, lenalidomide, thalidomide, alitretinoin, imiquimod, polyphenon, carboxyamidotriazole, TNP-470, CM101, IFN-alpha, IL-12, platelet factor-4, suamin, SU5416, thrombospondin, VEGFR antagonists, soluble VEGFR- 1, RP-1, angiopoietin-2, TSP-1, TSP-2, T P, CDA1 , Meth-1, Meth-2, prothrombin, antithrombin III, VEG-1, SPARC, osteopontin, maspin, can
  • An "isolated" polynucleotide is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in its natural source.
  • An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the specific nucleic acid molecule as it exists in natural cells.
  • nucleic acid sequence identity means the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in a nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
  • Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. When comparing DNA and RNA, thymine (T) and uracil (U) may be considered equivalent.
  • differential expression means qualitative or quantitative differences in the expression pattern of one or more polynucleotides, including miRNA, in a body fluid, cell, or tissue. Expression of the one or more polynucleotides may be upregulated, resulting in an increased amount of transcripts, or downregulated, resulting in a decreased amount of transcripts. Expression of the one or more polynucleotides may be upregulated or downregulated in a particular state, such as a disease state, relative to a reference state, such as a normal state, thus permitting comparison of two or more states.
  • the one or more polynucleotides may exhibit a pattern of expression in said body fluid, cell, or tissue that is detectable by standard techniques, including but not limited to expression arrays, quantitative reverse transcriptase PCR, northern analysis, and real-time PCR. Some of the polynucleotides may be expressed in one state but not another.
  • gene includes any polynucleotide sequence or portion thereof with a functional role in encoding or transcribing a protein or regulating other gene expression or producing a non-coding RNA such as a microRNA.
  • the gene may consist of all the nucleic acids responsible for encoding a functional protein or only a portion of the nucleic acids responsible for encoding or expressing a protein.
  • the polynucleotide sequence may contain a genetic abnormality within exons, introns, initiation or termination regions, promoter sequences, other regulatory sequences or unique adjacent regions to the gene.
  • Hybridization generally depends on the ability of denatured DNA or RNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so.
  • Stringent conditions or “high stringency conditions” are sequence dependent and can vary dependent upon circumstances. Stringent conditions can be selected to be about 5-10°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength pH.
  • T m can be the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium.
  • Stringent conditions include those in which the salt concentration is less than about 1.0 M sodium ion, such as about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., about 10-50 nucleotides) and at least about 60°C for long probes (e.g., greater than about 50 nucleotides). Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide.
  • Exemplary stringent condition include those that: (1) employ low ionic strength and high temperature for washing, for example 0.0 15 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) overnight hybridization in a solution that employs 50% formamide, 5xSSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5x Denhardt's solution, sonicated salmon sperm DNA (50 pg/ml), 0.1 % SDS, and 10% dextran sulfate at 42°C
  • Modely stringent conditions may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent than those described above.
  • moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C.
  • 5x SSC 150 mM NaCl, 15 mM trisodium citrate
  • 50 mM sodium phosphate pH 7.6
  • 5x Denhardt's solution 10% dextran sulfate
  • 20 mg/ml denatured sheared salmon sperm DNA followed by washing the filters in 1 x SSC at about 37-50°C.
  • the skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
  • cancer refers to or describes the physiological condition in animals, including humans, that is typically characterized by unregulated cell growth.
  • cancer examples include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple myeloma and B-
  • Tumor refers to malignant neoplastic cell growth and proliferation, and all pre-cancerous and cancerous cells and tissues.
  • Carriers as used herein include pharmaceutically acceptable carriers, exciplents, or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
  • physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM.
  • buffers such as phosphate, citrate, and other organic acids
  • antioxidants including ascorbic acid
  • proteins such as serum albumin,
  • Treatment is an intervention performed with the intention of preventing the development or altering the pathology of a disease or disorder. Accordingly, “treatment” refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disease or disorder as well as those in which the disease or disorder is to be prevented.
  • a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.
  • MicroRNAs are small, noncoding RNAs that influence gene regulatory networks by post-transcriptional regulation of specific messenger RNA targets. MicroRNA expression is dysregulated in human malignancies, frequently leading to overexpression or loss of expression of certain microRNAs.
  • MiRNAs associated with specific cancer include those listed in Table 1 :
  • human miR-210 (hsa-miR-210) has the symbol HGNC:MIR210 and the precursor sequence:
  • the mature sequence, hsa-miR-210 has the following structure
  • hsa-miR-210 has the following stem-loop structure (in which bold nucleotides indicate the segment that is selected during processing to yield the mature molecule, hsa-miR-210):
  • MicroRNAs are also involved in the development and function of the cardiovascular system. For example, specific miRNAs have been implicated in vascular angiogenesis and cardiomyocyte apoptosis, and also in the development of cardiac hypertrophy, arrhythmia, and heart failure.
  • sequences in Table 2 are sequences of mature forms of the miRNAs listed. DNA or RNA corresponding to the reverse complement of these could be used as probes to measure miRNAs in the blood.
  • miRNA Variation levels of mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, or miR-425-5p can be useful in predicting non-responsiveness.
  • Mature miRNAs are described herein as useful biomarkers having specific nucleotide sequences.
  • the sequence of each biomarker can also be varied, for example, due to genetic variation between individuals, i.e., SNPs, known to exist for some miRNAs and more likely to be discovered.
  • MicroRNA variation can result from changes due to RNA editing.
  • MicroRNA variants can have up to 3 substituted or deleted nucleotides at one or both of the 5' and 3' ends of the miRNA.
  • MicroRNA sequences can vary at the 5' and 3' end (though more commonly at the 3' end), due to various factors, including imprecise cleavage by enzymes such as the Dicer enzyme during miRNA maturation, as well as non- templated addition of nucleotides.
  • a variant of mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, or miR-425-5p as referred to herein preferably has a sequence with at least 80%, 85%, 90% 95%, or more identity with mature sequence of mir-100, miR-141, miR- 148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, or miR-425-5p.
  • the disclosure provides methods for detecting and identifying extracellular miRNA, for example, in a body fluid.
  • miRNA is isolated from a body fluid such as serum or plasma, the isolated miRNA is converted to cDNA, and amplified.
  • microRNA can be detected by various methods known to detect mRNA, including northern blotting, ribonuclease protection assay (RPA), reverse
  • RNA transcription polymerase chain reaction
  • ISH in situ hybridization
  • RNA purification no RNA purification, no reverse transcription, and no target amplification is required.
  • New methods and systems for non-PCR-based RNA detection that does not require purification of the RNA is available, for example, from Gen-Probe, Inc.
  • Third Wave Technologies also has described a miRNA detection technology that does not involve PCR, and that can be performed directly in lysates of a biological samples.
  • Kits for isolating RNA, and in particular miRNA, from a biological sample are known and commercially available, such as the mirVanaTM miRNA isolation kits (Ambion, Austin, TX). However, not all RNA isolation methods retain the small RNA fraction.
  • the method for isolating RNA from a body fluid should be adapted to retain the small RNA fraction, for example, less than 40 nucleotides. Examples of suitable kits include, but are not limited to, the mzVVanaTM PARISTM and mzVVanaTM miRNA isolation kits (Ambion, Austin, TX).
  • the miRNA isolation method retains the small RNA fraction in a background of total RNA or as an enriched fraction of RNA species.
  • the retained RNA species are 200 nucleotides or smaller, 150 nucleotides or smaller, 100 nucleotides or smaller, 50 nucleotides or smaller, 40 nucleotides or smaller, 30 nucleotides or smaller, 25 nucleotides or smaller.
  • cDNA can be generated by reverse transcription of isolated miRNA using reverse transcription conventional techniques.
  • miRNA reverse transcription kits are known and commercially available. Examples of suitable kits include, but are not limited to, mirVanaTM TaqMan® miRNA transcription kit (Ambion, Austin, TX) and the TaqMan® miRNA transcription kit (Applied Biosystems, Foster City, CA). Specific primers, including miRNA-specific stem-loop primers, are known and commercially available, for example, from Applied Biosystems (Foster City, Ca), Ambion (Austin, TX), and Qiagen (Valencia, CA).
  • the reverse transcript of the miRNA can be amplified using conventional PCR techniques including, but not limited to, real time PCR.
  • Kits for quantitative real time PCR of RNA and miRNA are known and commercially available. Examples of suitable kits include, but are not limited to, the TaqMan® MicroRNA Assay (Applied Biosystems, Foster City, CA) and the mirVanaTM qRT-PCR miRNA Detection Kit (Ambion, Austin, TX).
  • One example of a suitable primer set is the mz ' rVanaTM qRT-PCR primer set (Ambion, Austin, TX).
  • RNA can be ligated to a single stranded oligonucleotide containing universal primer sequences, a polyadenylated sequence, or adaptor sequence prior to reverse transcriptase and amplified using a primer complementary to the universal primer sequence, poly(T) primer, or primer comprising a sequence that is complementary to the adaptor sequence.
  • RNA control No established endogenous small RNA control is known for normalization of technical variations in sample processing or of potential variation in sample quality.
  • sample quality of a body fluid such as plasma
  • PCR inhibitors due to occult red blood cell lysis in plasma samples.
  • Normalizing by matching the amount of input RNA into the reverse transcription reaction is not an appropriate approach because the RNA content of the body fluid can vary considerably and may vary with disease states. Therefore, a fixed volume of RNA eluate from a given volume of starting body fluid, rather than a fixed mass of RNA, can be used as input into the reverse transcription reaction.
  • RNA derived from approximately 8.3 ⁇ of starting body fluid For example, for a sample in which the starting body fluid volume was 400 pi, an input of 1.67 ⁇ of eluted RNA (taken from a total RNA eluate volume of approximately 80.4 p i) into the reverse transcription reaction corresponds to the mass of RNA derived from approximately 8.3 ⁇ of starting body fluid.
  • the data can be normalized by spiking-in one or more RNA oligonucleotide that is sufficiently distinct from the sequences normally present in the sample, for example, an miRNA obtained from a non-human species where an identical or similar human species miRNA does not exist or a synthetic sequence designed to be distinct in the sample. Any sequence that is sufficiently distinct from the sequences to be measured, but which can be measured by similar assays, is a viable candidate for a spike-in control sequence. RNAs that do not cross hybridize with probes for known human miRNA, such as C.
  • elegans miRNAs cel-miR-39, cel-miR-54, and cel-miR-238 are spiked-in after addition of the denaturing solution to the body fluid to avoid degradation by endogenous plasma RNases.
  • the spiked-in miRNAs can be measured using, for example, TaqMan® qRT- PCR assays.
  • the number of copies of a given miRNA in each sample can be multiplied by the Normalization_Factor corresponding to the sample to obtain a normalized copy number value. In cases where it is desirable to apply
  • Normalized-Ct value for the miRNA in the sample Raw_Ct value - [(SpikeIn_Average_Ct value of the given sample) - (Median_SpikeIn_Ct value)].
  • novel miRNAs may require the development of custom qRT-PCR assays for their measurement.
  • Custom qRT-PCR assays to measure novel micro miRNAs in a body fluid can be developed using a robust method that involves an extended reverse transcription primer and locked nucleic acid modified PCR (Raymond et ah, 2005, RNA 11(11): 1737-44). Although several qRT-PCR methods have been reported for measuring miRNAs, extended reverse transcription primer and locked nucleic acid modified PCR is likely to provide the greatest specificity.
  • Custom miRNA assays can be tested by running it on a dilution series of chemically synthesized miRNA corresponding to the target sequence. This permits determination of the limit of detection and linear range of quantitation of each assay. Furthermore, when used as a standard curve, these data permit an estimate of the absolute abundance of endogenous miRNAs measured in body fluid samples.
  • a body fluid sample such as blood, serum, or plasma
  • a body fluid sample can be obtained from a single individual or pooled, for example, from a group of individuals suffering from a particular disease or disorder.
  • MicroRNA can be isolated from the sample by any number of methods, for example, as described herein, and the abundance of one or more microRNA can be determined by any of a number of methods, for example by calculating average Ct values.
  • Data for each candidate miRNA in a given sample can be normalized by subtracting the Reference Ct for that sample. Normalized data can be represented by a Act value
  • Amplification curves are checked to verify that Ct values are assessed in the linear range of each amplification plot. Typically, the linear range spans several orders of magnitude.
  • a chemically synthesized version of the miRNA can be obtained and analyzed in a dilution series to determine the limit of sensitivity of the assay, the linear range of quantitation, and to estimate the absolute abundance of the candidate miRNAs measured.
  • the methods described herein provide a rapid and non-invasive assay for prognosing the outcome of a cancer treatment in an individual.
  • Prognosis refers to the probable outcome of a disease, preferably when a patient is diagnosed as having a tumor, and, more preferably, when the patient is diagnosed as having a cancer.
  • the prognosis of a cancer includes the probable outcomes of using a treatment modality, preferably when the treatment involves use of angiogenesis therapeutic drug, most preferably when the treatment involves use of an anti- angiogenic therapeutic drug.
  • the prognosis can include an outcome in which the cancer is refractory to a possible treatment modality, preferably where the treatment modality will improve the prospects for recovery, increase the chances of survival, reduce the recovery period for the cancer, or minimize the probability of recurrence of the cancer.
  • the method of prognosis will identify a suitable treatment modality to improve the probability of a favorable outcome for the patient.
  • a favorable outcome is one in which the cancer patient has at least a 70% chance, and preferably an 80% chance that the cancer will not recur or metastasize within 2, 3, 4, 5, 6, 7, 8, 9, 10 or more years from beginning a therapeutic regime.
  • the treatment regime is related to the level of mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, or miR-425-5p in the blood, serum or bodily fluid of the patient.
  • treatment causes a change in blood mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR- 375, or miR-425-5p levels in cancer patient.
  • the prognosis and the outcome of the treatment is favorable or unfavorable, depending on the direction of the change.
  • anti-angiogenic treatment does not cause a change in
  • the prognosis is not favorable, because the cancer may be refractory to treatment.
  • a cancer patient presents with high levels of blood mir- 100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, or miR-425-5p and is refractory to an anti-angiogenic therapy.
  • the patient should be switched to a pro-angiogenic drug to stabilize the blood supply to the cancer and then to treat with a cytotoxic agent, e.g., a
  • a cancer patient presents with a low level of blood mir- 100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, or miR-425-5p. This patient likely will have a favorable prognosis when an anti-angiogenic drug is administered.
  • Whether a level of mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR- 210, miR-222, miR-375, or miR-425-5p is high for a specific cancer may be determined by the ordinary skilled worker from a clinical trial conducted with that cancer. In one instance, whether a blood level of mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR- 222, miR-375, or miR-425-5p is low or high depends from a standard value which is predetermined for the specific cancer. In another instance, blood levels of miR-210 are low or high relative to an average value obtained from normal, healthy subjects.
  • whether blood levels of mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR- 222, miR-375, or miR-425-5p are low depends on an average value obtained from different patients with the same cancer.
  • the reference value is a median obtained by factoring the average value from similar cancer patients.
  • the level of miR-210 may be normalized by comparing it to the level of a control gene. The skilled person can realize that the reference value may be chosen depending on factors as the normalization method and the control values used.
  • the methods include determining the relative amount of miR-210 in an extracellular sample, for example, body fluid obtained from an individual.
  • the amount of miR-210 in a body fluid can be compared to a control, for example a matched sample of normal body fluid, a previously analyzed sample, or a suitable standard control developed for the particular assay.
  • kits adapted for the determination of microRNA biomarkers and diagnoses of disease are provided herein.
  • Such kits may include materials and reagents adapted to specifically determine the presence and/or amount of a microRNA biomarker or group of miRNA biomarkers selected to be diagnostic of disease in a sample of body fluid.
  • the kit can include nucleic acid molecules or probes in a form suitable for the detection of said miRNA biomarkers.
  • the nucleic acid molecules can be in any composition suitable for the use of the nucleic acid molecules according to the instructions.
  • the kit can include a detection component, such as a microarray, a labeling system, a cocktail of components (e.g., suspensions required for any type of PCR, especially real-time quantitative RT-PCR), membranes, color-coded beads, columns and the like.
  • a detection component such as a microarray, a labeling system, a cocktail of components (e.g., suspensions required for any type of PCR, especially real-time quantitative RT-PCR), membranes, color-coded beads, columns and the like.
  • the kit can include a container, pack, kit or dispenser together with instructions for use.
  • a diagnostic kit may contain, for example, forward and reverse primers designed to amplify and detect the microRNA in body fluid.
  • Many different PCR primers can be designed and adapted as necessary to amplify one or more miRNA that are differentially expressed in a body fluid and correlate to a particular disease or disorder.
  • the primers are designed to amplify a miRNA or group of miRNA that are differentially expressed in a body fluid of an individual having cancer or at risk of developing cancer.
  • the diagnostic kit may also contain single stranded oligonucleotide containing universal primer sequences, polyadenylated sequences, or adaptor sequences prior and a primer complementary to said sequences.
  • the miRNA isolated from the body fluid is ligated to the single stranded oligonucleotide containing universal primer sequence, polyadenylated sequence, or adaptor sequence prior to reverse transcription and amplified with said complementary primers.
  • the kit comprises primers that amplify one of more of the miRNA shown above.
  • poly-A-tailing is used to generate a sequence that can then be hybridized to a poly-T primer that is used for reverse
  • microarrays comprising the miRNA biomarkers of the invention.
  • Microarrays can be used to measure the expression levels of large numbers of miRNAs simultaneously.
  • Microarrays can be fabricated using a variety of technologies, including printing with fine-pointed pins onto glass slides, photolithography using pre-made masks, photolithography using dynamic micromirror devices, ink-jet printing, or electrochemistry on microelectrode arrays, Also useful are microfluidic
  • TaqMan® Low-Density Arrays based on an array of microfluidic qRT-PCR reactions as well as related microfluidic qRT-PCR based methods.
  • Microarrays can be used for the expression profiling of miRNAs in diseases, such as cancer.
  • RNA is extracted from the body fluid and the miRNAs are size-selected from total RNA.
  • Oligonucleotide linkers are attached to the 5' and 3' ends of the miRNAs and the resulting ligation products are used as templates for an RT-PCR reaction.
  • the sense strand PCR primer can have a fluorophore attached to its 5' end, thereby labeling the sense strand of the PCR product.
  • the PCR product is denatured and then hybridized to the microarray.
  • a PCR product referred to as the target nucleic acid that is complementary to the corresponding miRNA capture probe sequence on the array will hybridize, via base pairing, to the spot at which the, capture probes are affixed.
  • the spot will then fluoresce when excited using a microarray laser scanner.
  • the fluorescence intensity of each spot is then evaluated in terms of the number of copies of a particular miRNA, using a number of positive and negative controls and array data normalization methods, which will result in assessment of the level of expression of a particular miRNA.
  • total RNA containing the miRNA extracted from a body fluid sample can be used directly without size-selection of the miRNAs, and the RNA is 3' end labeled using T4 RNA ligase and a fluorophore-labeled short RNA linker.
  • Fluorophore- labeled miRNAs complementary to the corresponding miRNA capture probe sequences on the array hybridize, via base pairing, to the spot at which the capture probes are affixed. The fluorescence intensity of each spot is then evaluated in terms of the number of copies of a particular miRNA, using a number of positive and negative controls and array data normalization methods, which will result in assessment of the level of expression of a particular miRNA.
  • microarrays can be employed including, but not limited to, spotted oligonucleotide microarrays, pre-fabricated oligonucleotide microarrays or spotted long oligonucleotide arrays.
  • Additional methods for miRNA detection and measurement include, for example, strand invasion assay (Third Wave Technologies, Inc.), surface plasmon resonance, cDNA, MTDNA (metallic DNA; Adnassemble Technologies, Saskatoon, SKI, single-molecule methods such as the one developed by US Genomics, etc.
  • the primary prostate epithelial and primary prostate stromal cells can be cultured by the methods described in Gmyrek 2001 , Am J. Pathol. 159:579-90 (Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.) .
  • Human prostate cancer-derived cells 22Rvl cells
  • RPMI 1640 GEBCO®
  • Xenografts were established in NOD/SCID mice by subcutaneous injection of 7.5xl0 5 22Rvl cells per mouse. Mouse blood was collected by cardiac puncture at 28 days following injection.
  • miRNAs that were quantified using TaqMan® miRNA qRT-PCR assays with modifications as described below:
  • RNA assay of a sample of RNA isolated from serum or plasma a fixed volume of 1.67 ⁇ of RNA solution from the approximate 80.4 ⁇ eluate from RNA isolation of a given sample was input into the reverse transcription (RT) reaction.
  • RNA is isolated from a 400 ⁇ plasma or serum sample.
  • a 1.67 ⁇ RNA solution represents the RNA corresponding to (1.67/80.4)*400 or 8.3 ⁇ of plasma or serum.
  • varying dilutions of each oligonucleotide were made in water such that the final input into the RT reaction has a volume of 1.67 ⁇ .
  • Input RNA is reverse transcribed using the TaqMan® miRNA Reverse Transcription Kit and miRNA-specific stem-loop primers (Applied BioSystems, Inc.) in a small-scale RT reaction containing 1.387 ⁇ H 2 0, 0.5 ⁇ 10X Reverse-Transcription Buffer, 0.063 ⁇ RNase-Inhibitor (20 U/ ⁇ ), 0.05 ⁇ 100 mM dNTPs with dTTP, 0.33 ⁇ MultiscribeTM Reverse-Transcriptase and 1.67 ⁇ input RNA.
  • Components other than the input RNA are prepared as a larger volume master mix using a Tetrad® 2 Peltier Thermal Cycler (BioRad) at 16°C for 30 minutes, at 42°C for 30 minutes, and at 85°C for 5 minutes.
  • Standard curves were generated for each miRNA assay using a dilution series of known input amounts of synthetic miRNA oligonucleotide corresponding to the target of the assay.
  • the dilution series samples were run with common RT and PCR enzyme master mixes on the same plate as experimental samples. Data points where measured Ct was interpreted to be below the linear range of the assay were not used for derivation of the trend line.
  • Synthetic single-stranded RNA oligonucleotides corresponding to the mature miRNA sequence can be purchased, e.g., from IDT, Sigma, or Qiagen. Synthetic miRNAs are input into the RT reaction over an empirically-derived range of copies to generate standard curves for each of the miRNA TaqMan® assays listed above.
  • the lower-limit of accurate quantification for each assay is designated based on the minimal number of copies input into an RT reaction that resulted in a Ct value within the linear range of the standard curve and that was also not equivalent to or higher than a Ct obtained from an RT input of a lower copy number.
  • the absolute copies of miRNA input into the RT reaction are converted to copies of miRNA per microliter of plasma (or serum) based on the knowledge that the material input into the RT reaction corresponds to RNA from 2.1 % of the total starting volume of plasma (i.e., 1.67 ⁇ of the total RNA eluate volume (80.4 ⁇ on average) was input into the RT reaction).
  • the layout of the samples in the reverse transcription, pre-amplification, and real-time PCR reactions in the strip tubes and multi-well plates are designed to minimize the chance of cross-contamination by the standard curve samples and to minimize systematic bias when comparing groups, such as xenografted mice and control mice.
  • Experimental samples can be separated from standard curves by at least one empty row.
  • RNA samples from the xenografis and the controls were blinded and randomized in the layout on the PCR plate.
  • case and control samples were alternated in sequence to avoid geographic location bias on the PCR plate.
  • RNA derived from approximately 8.3 ⁇ of starting plasma For example, for a sample in which the starting plasma volume was 400 ⁇ , an input of 1.67 ⁇ of eluted RNA (taken from a total RNA eluate volume of approximately 80.4 ⁇ ) into the RT reaction corresponds to the mass of RNA derived from approximately 8.3 ⁇ of starting plasma.
  • RNA oligonucleotides corresponding to miRNAs that do not exist in the mouse or human genomes. These RNAs were synthesized to match the sequence of three C. elegans miRNAs, cel-miR-39, cel-miR-54, and cel-miR-238 (purchased as custom RNA
  • oligonucleotide syntheses from Qiagen and were confirmed empirically as not cross- hybridizing with probes for known human miRNAs on a locked nucleic acid-probe-based microRNA microarray (data not shown).
  • the spiked-in oligos were introduced (as a mixture of 25 fmol of each oligonucleotide in a 5 ⁇ total volume of water) after addition of 2X Denaturing Solution (Ambion) to the plasma or serum sample to avoid degradation by endogenous plasma RNases.
  • 2X Denaturing Solution Ambion
  • the C. elegans spiked-in miRNAs were measured using TaqMan® qRT-PCR assays (Applied BioSystems, Inc.) as described herein.
  • SpikeIn_Average_Ct values obtained from all the samples to be compared was next calculated (designated here as the Median_SpikeIn_Ct value).
  • Normalized_Ct value for the miRNA in the sample Raw_Ct value - [(SpikeIn_Average_Ct value of the given sample) - (Median_SpikeIn_Ct value)]
  • NOD/SCID mice (Strain NOO.C ll -Prkdc scid n, stock/ number 0013031), were purchased from Jackson Labs (Bar Harbor, ME) and bred in-house. The mice were housed at a density of five mice per cage in an SPF environment in laminate airflow units changed once per week.
  • 22Rvl cells were harvested for injection with trypsin (0.05%)-EDTA solution, washed with culture medium and resuspended in a solution of ice-cold 50% basement membrane matrix (BD MatrigelTM) in Hank's Balanced Salt Solution (GIBCO®) at a concentration of 7.5xl0 6 cells/ml.
  • trypsin 0.05%)-EDTA solution
  • GEBCO® Hank's Balanced Salt Solution
  • Xenografts were established in NOD/SCID mice by subcutaneous injection at the hip of 7.5x10 5 cells/mouse in 200 ⁇ total volume cell-MatrigelTM-HBSS suspension. All xenograft mice developed grossly visible tumors.
  • mice were treated with a control antibody or with an anti-angiopoietin 2 antibody (Anti-AGPT2 Ab) (Amgen Inc.). All mice were sacrificed 28 days post-injection. Prior to sacrifice, the mice were anesthetized by an intra-peritoneal injection of 500 ⁇ Avertin® (Sigma- Aldrich, St. Louis, MO) and blood was collected by cardiac puncture. This was followed by euthanasia and cervical dislocation. Each tumor was harvested in its entirety, snap frozen in liquid nitrogen, and stored at -80°C.
  • Anti-AGPT2 Ab Anti-AGPT2 Ab
  • Ct values were converted to absolute number of copies/ ⁇ plasma using a dilution series of known input quantities of synthetic target miRNA run simultaneously (on the same plate) as the experimental samples. Values shown have been normalized using measurements of C. elegans synthetic miRNA controls spiked into plasma after denaturation for RNA isolation.
  • Table 3 shows results of measurement of serum miR-210 in mice bearing prostate cancer xenografts, either treated with control Ab or with anti-Angiopoietin 2 therapeutic antibody.
  • An ideal extracellular biomarker of a disease or disorder for example, to be detected in extracellular fluid such as plasma or serum, is one that is highly disease specific.
  • the extracellular ideal biomarker would show very low or absent expression in normal extracellular fluid, and its detection and/or abundance in extracellular fluid would be indicative of disease.
  • Table 4 lists results of TLDA TaqMan® qRT-PCR assay of human normal blood for the listed microRNAs, which have nucleotide sequences corresponding to those listed in Table 2, above.
  • Cancer MicroRNA Marker Low/absent expression in healthy donor human plasma.
  • Ct values represents cycle threshold values obtained from qRT-PCR analysis of the indicated miRNA.
  • the miRNA is expressed at extremely low/absent level in normal plasma, as Ct values greater than 30 indicate extremely low or absent expression.
  • miRNA expressed at very low or absent levels in healthy donor human plasma can be evaluated for correlation to disease and detection in extracellular fluids of individuals suffering from the disease or disorder.
  • miR-210 in normal subjects is at low levels or is absent.
  • Global profiling of serum miRNAs identifies elevation of microRNAs in serum of prostate cancer patients.
  • Figures 1A-1F show the results of measuring miRNA in blood from patients with prostate cancer.
  • Figure 1 A shows results of measurement of circulating miRNAs in sera pooled from patients with advanced prostate cancer or healthy donors by TLDA profiling.
  • Figure 1A shows that mir-100, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, and miR-425-5p met biomarker criterion of >5-fold change (unadjusted P ⁇ 0.05, student's t-test) in pooled sera from CaP patients relative to normal controls.
  • the data are presented in Table 5.
  • Table 5 Table 5
  • FIGS 1B-F show results of measuring miRNA biomarker candidates levels in individual samples by TaqMan® miRNA qRT-PCR (P value assigned by Wilcoxon signed-rank test). Levels of miRNA is given in terms of miRNA copies/ ⁇ serum. The horizontal bars show the mean value +/- SEM of miRNA copies/ ⁇ serum for each group. The lower panels show receiver operating characteristic (ROC) curves plot sensitivity vs. (1 - specificity) to assess the ability of each miRNA biomarker to distinguish CaP and control sera. AUC, area under the curve; CaP, prostate cancer patient sera; FC, fold-change; N, normal sera (PSA neg /DRE neg ).
  • ROC receiver operating characteristic
  • Serum levels of miR-210 distinguish patients with advanced prostate cancer that are either responding or not responding to therapy.
  • Figures 2A-2E show copies of miR-210 per microliter serum plotted for individuals with whose prostate cancer was responding to therapy (defined as being in a period of declining PSA at the time the blood was drawn for microRNA measurement) or not responding (defined as being in a period of not changing or increasing PSA when the blood was drawn for microRNA measurement).
  • Serial serum PSA values define treatment response, using PSA as a measure of tumor burden.
  • serum miR-210 levels distinguish patients responding to therapy from those who are not responding, whereas serum levels of miR-141, miR-200a, miR-200c, and miR-375, other prostate cancer-associated microRNA biomarkers, do not.
  • the other biomarkers reflect disease burden and efficiency of overall miRNA release by the cancer. Results of measuring these miRNAs could be used singly or as a means to calculate miR-210 levels in a given patient normalized to disease burden.
  • aspects of the present disclosure may take place on a general computing device. Aspects of storing, manipulating, calculating, configuring, or displaying data, prognosing and/or any other computing operations may be performed by a computing device. Examples of well known computing systems, environments, and/or configurations that may be suitable include, but are not limited to, personal computers, server computers, hand held or laptop devices, smartphones, multiprocessor systems,
  • microprocessor-based systems set top boxes, programmable consumer electronics, network PCs, minicomputers, mainframe computers, distributed computing environments and the like.
  • An example computing device may comprise one or more processors and one or more memories.
  • the memories may be coupled to the one or more processors.
  • the memories may be coupled to the one or more processors by a system bus, which may be of a type of bus structure known in the art, including a memory bus or memory controller, a peripheral bus, and a local bus using any of a variety of bus architectures.
  • the memories may be read only memory (ROM), random access memory (RAM) and the like.
  • a basic input/output system (BIOS) may be used to transfer data and information between elements within the computing device.
  • a computing device may include disks and drives for writing and reading data. These may be hard drives, floppy drives, removable storage, optical disks, magnetic discs, magnetic cassettes, flash memory, or any other disk or drive for storing data.
  • the disks and drives may be computer readable media and may have stored thereon instructions that when executed by a processor cause the processor to perform one or more actions included herein.
  • a computing device may be associated with one or more user inputs, such as, for example, a mouse, a keyboard, a voice recorder, touchscreen, joystick, a camera, a medical device with digital output and the like. These and other peripheral input devices may be connected via serial or parallel port to the system bus or any other interface.
  • a monitor, tv, touchscreen, or other type of display device may also be connected to the system bus via an interface such as a video adapter. The same may be true for a printer, a video output, or speakers.
  • a computing device may be in a network environment with one or more logical connections to one or more computers. These may include servers, routers, PCs, network nodes and the like. Data and information may be sent and received by the computing device and may be manipulated.
  • a computing device may be configured to receive data related to one or more measurements of miR-210.
  • the data related to one or more measurements of miR-210 may be stored in a memory associated with the computing device.
  • the one or more measurements may be stored in a database. These data may be configured to provide indications of the efficacy of the prognosis for various levels of miR-210 as indicated above.
  • a series of trials related to miR-210 may provide information indicative of the one or more levels of miR-210 based on one or more trials, as well as information indicative of one or more prognoses. Other information indicative of one or more elements related to each prognosis may also be included.
  • the information indicative of the one or more levels of miR-210, the information indicative of the one or more prognoses and the information indicative of one or more elements related to the prognosis may be stored in a database.
  • information indicative of one or more elements related to clinical markers of the cancer is provided.
  • the database may be configured as a tool for prognosis.
  • the database may be used as a comparison for data indicative of the levels of miR210.
  • a patient may have their levels of miR210 measured. This measurement may be compared to one or more outputs of the database, such as, for example, calculations, similar prognosis factors, patient similarities and the like.
  • the database may be configured to provide a graphical display of the levels of miR-210 and prognosis.
  • the data in the database may be displayed on a display device, or it may be used in one or more calculations.
  • a calculation may comprise a prognosis of a patient associated with the data.
  • the computing device may be configured to provide an output related to the prognosis of a patient as a response to receiving one or more measurements of miR-210.
  • computer readable medium may have stored thereon instructions that when executed by a processor may cause the processor to receive data indicative of one or more levels of miR-210, manipulate the data, store the data, place the data in a database, subject the data to one or more calculations such as those described herein, and provide a prognosis.
  • a computing device or computer readable medium may be configured to send data indicative of one or more levels of miR-210; receive, as a response to the sending, an indication of the prognosis of a subject; and display, on a display, the prognosis of the subject.
  • the database above may be used to instruct a researcher or a person in control of choosing an appropriate therapy on the basis of the prognosis of cancer patient.

Abstract

La présente invention a pour objet une méthode de pronostic du cancer pendant une thérapie antiangiogénique par la mesure des niveaux de miR-210 dans le sang. Le pronostic est basé sur des modifications des niveaux de miR-210 qui résultent de la thérapie. Cette méthode fournit également un moyen de prédiction du résultat d'une thérapie antiangiogénique.
PCT/US2011/040078 2010-06-10 2011-06-10 Utilisation du mir-210 sanguin pour le pronostic du cancer WO2011156777A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35341410P 2010-06-10 2010-06-10
US61/353,414 2010-06-10

Publications (1)

Publication Number Publication Date
WO2011156777A1 true WO2011156777A1 (fr) 2011-12-15

Family

ID=44262594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/040078 WO2011156777A1 (fr) 2010-06-10 2011-06-10 Utilisation du mir-210 sanguin pour le pronostic du cancer

Country Status (1)

Country Link
WO (1) WO2011156777A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116742A1 (fr) * 2012-02-01 2013-08-08 Mayo Foundation For Medical Education And Research Prédiction de réponses à une thérapie par privation androgénique et procédés pour traiter le cancer de la prostate
WO2013107460A3 (fr) * 2012-01-16 2013-09-12 Herlev Hospital Micro-arn pour prédiction de l'efficacité d'un traitement et établissement d'un pronostic chez des patients atteints d'un cancer
WO2015057806A1 (fr) * 2013-10-15 2015-04-23 The Board Of Trustees Of The University Of Illinois Des micro-arn de sérum pour le pronostic du cancer de la prostate
EP2986739A4 (fr) * 2013-04-15 2017-03-01 Regeneron Pharmaceuticals, Inc. Marqueurs de la réponse d'une cellule tumorale à un traitement anticancer
EP3622071A4 (fr) * 2017-05-10 2020-05-20 Nantomics, LLC Arn circulant pour la détection, la prédiction et la surveillance du cancer
CN112813170A (zh) * 2021-04-09 2021-05-18 黄小容 一种用于宫颈癌筛查的试剂盒及其使用方法
CN113151280A (zh) * 2021-05-27 2021-07-23 暨南大学 一种小分子非编码rna及宿主基因在胃癌诊断及治疗的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306017A1 (en) 2006-01-05 2008-12-11 The Ohio State University Microrna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer
US20080306006A1 (en) 2006-01-05 2008-12-11 The Ohio State University MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
US20090044906A1 (en) 2007-08-16 2009-02-19 Evonik Degussa Gmbh Method for decorating surfaces
WO2009131887A2 (fr) * 2008-04-24 2009-10-29 Merck & Co., Inc. Procédés d’utilisation de mir-210 comme biomarqueur de l’hypoxie et comme agent thérapeutique dans le traitement du cancer
WO2009143379A2 (fr) * 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Utilisation d’arn extracellulaire pour mesurer une maladie
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306017A1 (en) 2006-01-05 2008-12-11 The Ohio State University Microrna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer
US20080306006A1 (en) 2006-01-05 2008-12-11 The Ohio State University MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
US20090044906A1 (en) 2007-08-16 2009-02-19 Evonik Degussa Gmbh Method for decorating surfaces
WO2009131887A2 (fr) * 2008-04-24 2009-10-29 Merck & Co., Inc. Procédés d’utilisation de mir-210 comme biomarqueur de l’hypoxie et comme agent thérapeutique dans le traitement du cancer
WO2009143379A2 (fr) * 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Utilisation d’arn extracellulaire pour mesurer une maladie

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ADRIAN M. JUBB ET AL: "Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 14, no. 1-2, 1 January 2010 (2010-01-01), pages 18 - 29, XP055003427, ISSN: 1582-1838, DOI: 10.1111/j.1582-4934.2009.00944.x *
CAMPS CARME ET AL: "hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 5, 1 March 2008 (2008-03-01), pages 1340 - 1348, XP002507074, ISSN: 1078-0432, DOI: DOI:10.1158/1078-0432.CCR-07-1755 *
CAMPS ET AL., CLIN CANCER RES, vol. 14, 2008, pages 1340 - 48
GEE ET AL., CANCER, vol. 116, 2010, pages 2148 - 58
GMYREK, AM J. PATHOL., vol. 159, 2001, pages 579 - 90
HARRIET E. GEE ET AL: "hsa-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer", CANCER, 1 January 2010 (2010-01-01), pages NA - NA, XP055003217, ISSN: 0008-543X, DOI: 10.1002/cncr.25009 *
HARRIS A: "Resistance to anti-angiogenic therapy induced by hypoxia and notch signalling", EJC SUPPLEMENTS, vol. 8, no. 3, March 2010 (2010-03-01), & EUROPEAN BREAST CANCER CONFERENCE; BARCELONA, SPAIN; MARCH 24 -24, 2010, pages 183 - 184, XP002652946, ISSN: 1359-6349 *
HO ET AL., J CLIN ONCOL, vol. 27, 2009, pages 15S
KULSHRESHTHA ET AL., MOL CELL BIOL, vol. 27, 2007, pages 1859 - 67
LAWRIE CHARLES H ET AL: "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma", BRITISH JOURNAL OF HAEMATOLOGY, BLACKWELL PUBLISHING LTD, vol. 141, no. 5, 1 June 2008 (2008-06-01), pages 672 - 675, XP002545705, ISSN: 1365-2141, [retrieved on 20080303], DOI: DOI:10.1111/J.1365-2141.2008.07077.X *
RAYMOND ET AL., RNA, vol. 11, no. 11, 2005, pages 1737 - 44
SAMBROOK: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR PRESS
SHI, CHIANG, BIOTECHNIQUES., vol. 39, 2005, pages 5 19 - 525
WARRIOR ET AL., J. BIOMOL. SCREEN., vol. 5, 2000, pages 343 - 52

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107460A3 (fr) * 2012-01-16 2013-09-12 Herlev Hospital Micro-arn pour prédiction de l'efficacité d'un traitement et établissement d'un pronostic chez des patients atteints d'un cancer
WO2013116742A1 (fr) * 2012-02-01 2013-08-08 Mayo Foundation For Medical Education And Research Prédiction de réponses à une thérapie par privation androgénique et procédés pour traiter le cancer de la prostate
EP2986739A4 (fr) * 2013-04-15 2017-03-01 Regeneron Pharmaceuticals, Inc. Marqueurs de la réponse d'une cellule tumorale à un traitement anticancer
US10023916B2 (en) 2013-04-15 2018-07-17 Regeneron Pharmaceuticals, Inc. Markers of tumor cell response to anti-cancer therapy
WO2015057806A1 (fr) * 2013-10-15 2015-04-23 The Board Of Trustees Of The University Of Illinois Des micro-arn de sérum pour le pronostic du cancer de la prostate
EP3622071A4 (fr) * 2017-05-10 2020-05-20 Nantomics, LLC Arn circulant pour la détection, la prédiction et la surveillance du cancer
CN112813170A (zh) * 2021-04-09 2021-05-18 黄小容 一种用于宫颈癌筛查的试剂盒及其使用方法
CN112813170B (zh) * 2021-04-09 2021-12-10 江苏达伯药业有限公司 一种用于宫颈癌筛查的试剂盒及其使用方法
CN113151280A (zh) * 2021-05-27 2021-07-23 暨南大学 一种小分子非编码rna及宿主基因在胃癌诊断及治疗的应用
CN113151280B (zh) * 2021-05-27 2023-10-20 暨南大学 一种小分子非编码rna及宿主基因在胃癌诊断及治疗的应用

Similar Documents

Publication Publication Date Title
US20230046649A1 (en) Microrna assay for detection and management of pancreatic cancer precursors
Resnick et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform
US11220713B2 (en) MicroRNAs as biomarkers for endometriosis
US9487776B2 (en) Method of identifying myelodysplastic syndromes
US20110160290A1 (en) Use of extracellular rna to measure disease
EP2800820B1 (fr) Procédés et trousses pour détecter des sujets atteints d'un cancer du pancreas
WO2011156777A1 (fr) Utilisation du mir-210 sanguin pour le pronostic du cancer
Usó et al. miRNA detection methods and clinical implications in lung cancer
EP2759602A1 (fr) Procédés de diagnostic génétique prénatal non invasif
WO2015095862A2 (fr) Biomarqueurs de micro-arn pour le cancer de l'ovaire
WO2011154008A1 (fr) Classification de micro-arn de néoplasie folliculaire de la thyroïde
EP3122905B1 (fr) Micro-arn circulants en tant que biomarqueurs pour l'endométriose
US20140106985A1 (en) Microrna biomarkers for prognosis of patients with pancreatic cancer
WO2010058393A2 (fr) Compositions et procédés pour le pronostic du cancer du côlon
EP2622097B1 (fr) Méthodes de pronostic, compositions et kits de prédiction d'une récidive de la leucémie aiguë lymphoblastique (lal)
WO2016160882A1 (fr) Procédés de diagnostic et de traitement du cancer colorectal au moyen de micro-arn549a
WO2010020787A1 (fr) Diagnostic et traitement des tumeurs
US9150926B2 (en) Diagnosis and treatment of adrenocortical tumors using human microRNA-483
CN111394464B (zh) 放射性损伤疾病的检测试剂及其应用
Rghebi Circulating nucleic acids as biomarkers of breast cancer
WO2010018585A2 (fr) Compositions et procédés de pronostic d'un mélanome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11726034

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11726034

Country of ref document: EP

Kind code of ref document: A1